ODI 2001
Alternative Names: ODI-2001Latest Information Update: 17 Jul 2024
At a glance
- Originator Odimma
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jul 2024 Odimma Therapeutics plans a phase I trial for Colorectal cancer (Late-stage disease) (SC, Injection)
- 31 May 2024 Immunogenicity and adverse events data from preclinical studies in Cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 02 May 2023 ODI 2001 is available for licensing as of 02 May 2023. http://sntpseditorial/adis2000www/script/citation/citationmain.asp?Adnm=9388161